This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Theranostics, the combination of diagnostics and therapies is a new concept in cancer management.
Our published work strongly suggests that orally administered multifunctional targeted ?nano-
bullets? (nanocarriers; NCs) with iron saturated bovine lactoferrin (Fe-bLf) were able to kill tumours.
Here for the first time, we are developed multifunctional-targeted nanocapsules conjugated with stably
modified aptamers to target and kill cancer as well as cancer stem cells. These nanocapsules labeled
with biosensors, will deliver anti-cancer molecules to colon tumours and help to monitor the therapy
in real-time imaging. A cell permeable dominant negative mutant form of survivin (dNSurR9C84A),
dNSurR9C84A has shown promising anticancer properties by inhibition of survivin and reduces the
chance of side effects since survivin is not expressed in normal cells in an adult. However due to short
half-life of dNSurR9C84A a drug delivery system based on low molecular weight chitosan was used
which could prolong the bioavailability of dNSurR9C84A. These chitosan nanoparticles were well
characterized before examining effects on colon cancer cells (Caco-2). The nanoparticle transport
studies were carried out both in vitro and ex vivo in order to understand the mechanism of low
molecular weight chitosan nanoparticles with intestinal cells. The in vivo Biodistribution studies showed
a highly selective and specific patter of uptake of the targeted nanocarriers or ?nanobullets? (CHNP-
dNSurR9C84A-LNA-Nu+Ep) in the tumour. The targeted nanocarriers were also able to significantly
inhibit the tumour volume up to a period of 95 days. These nanobullets showed specific internalization
in cancer stem cells and led to cancer stem cells specific apoptosis, thus proved to be appropriate for oral
administration in colon cancer.
Associate Professor Jagat R Kanwar is the Head of Nanomedicine-Laboratory of Immunology and Molecular
Biomedical Research (LIMBR). Dr. Jagat R Kanwar has received his Master?s degree in Medical Biochemistry and PhD
in Molecular Immunology from PGIMER, Chandigarh, India in 1992. He has an international reputation and expertise
in investigating fundamental and applied molecular signaling aspects of pathogenesis of cancer, chronic inflammation
and neurodegenerative diseases, thereby, leading to the development of treatment strategies from bench to bedside. He
has more than 100 publications in high impact factor and peer reviewed international journals, 27 book chapters and 3
edited books. Assoc Prof Kanwar?s research has generated several patents/PCTs with more than five licensed patents
for commercialization to BioPharma industry. His group is currently working on drug discovery and nanomedicine for oral
and systemic drug delivery of a range of biomacromolecules (proteins/peptides, siRNAs and aptamers) for targeting
survivin, HIF-1α and other apoptotic and inflammatory cell signaling molecules in cancer, chronic inflammation and
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals